quinazolines has been researched along with Cancer of the Thyroid in 173 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 24 (13.87) | 29.6817 |
| 2010's | 131 (75.72) | 24.3611 |
| 2020's | 18 (10.40) | 2.80 |
| Authors | Studies |
|---|---|
| Álvarez-Escolá, C; Castelo-Fernández, B; García-Moreno, RM; Moreno-Domínguez, Ó; Torres-Sánchez, I; Yébenes-Gregorio, L | 1 |
| Courtier, B; Hadoux, J | 1 |
| Brandenburg, T; Dralle, H; Führer, D; Muchalla, P; Schmid, KW; Theurer, S; Tiedje, V; Weber, F | 1 |
| Koehler, VF; Kroiss, M; Spitzweg, C | 1 |
| Hubalewska-Dydejczyk, A; Sokołowski, G; Suchmiel, M; Trofimiuk-Müldner, M; Wilczyńska, M | 1 |
| Bardet, S; Brose, MS; Capdevila, J; Elisei, R; Führer, D; Gao, M; Hadoux, J; Hoff, AO; Hu, MI; Isaev, P; Jarzab, B; Keam, B; Kopeckova, K; Lin, B; Lin, Y; Maeda, P; Robinson, BG; Sherman, EJ; Singh, R; Soldatenkova, V; Tahara, M; Wadsley, J; Wirth, LJ; Wright, J | 1 |
| Agate, L; Bottici, V; Cappagli, V; Ciampi, R; Elisei, R; Matrone, A; Molinaro, E; Piaggi, P; Ramone, T; Romei, C; Tacito, A; Valerio, L; Viola, D | 1 |
| Su, Z; Tang, J; Wang, H | 1 |
| Forssell-Aronsson, E; Montelius, M; Nilsson, O; Sandblom, V; Shubbar, E; Spetz, J; Ståhl, I; Swanpalmer, J | 1 |
| Bastholt, L; Colzani, R; Elisei, R; Foster, M; Haddad, R; Hauch, O; Jarząb, B; Kreissl, MC; Robinson, B; Schlumberger, M; Weiss, R | 1 |
| Barros Freiria, X; Calabia Martínez, J; Castillo Devia, M; García Méndez, I; Martin Alemany, N; Merino Ribas, A; Noboa Paez, C; Pérez Bueno, F; Pilco Teran, M; Rubio Casadevall, J; Torguet Escuder, P | 1 |
| Baudin, E; Berdelou, A; Borget, I; Hecht, F; Leboulleux, S; Ramos, HE; Schlumberger, M | 1 |
| Balcı, Y; Çağlar Çıtak, E; Demir Gündoğan, B; Sağcan, F; Tuğ Bozdoğan, S; Tuncel Daloğlu, F | 1 |
| Adam, P; Allelein, S; Berg, E; Frank-Raue, K; Hoster, E; Koehler, VF; Kroiss, M; Raue, F; Schott, M; Spitzweg, C | 1 |
| Chino, T; Ito, KI; Ito, T; Kanai, T; Maeno, K; Oba, T; Ono, M; Shimizu, T; Soma, A | 1 |
| Ahn, J; Jeon, MJ; Kang, HC; Kim, BH; Kim, HK; Kim, IJ; Kim, M; Kim, TY; Lim, DJ; Shong, YK; Yoon, JH | 1 |
| Ahn, HY; Chae, JE; Kim, SG; Moon, H; Noh, J; Park, YJ | 1 |
| Borghi, MO; Cantone, MC; Carra, S; Dicitore, A; Gaudenzi, G; Ghilardi, A; Hofland, LJ; Persani, L; Plebani, A; Saronni, D; Vitale, G | 1 |
| Cohen, PR; Udkoff, J | 1 |
| Chen, L; Cheng, L; Jin, Y; Liu, M; Ruan, M | 1 |
| Hong, SK; Park, JI; Starenki, D; Wu, PK | 1 |
| Cochin, V; Godbert, Y; Gross-Goupil, M; Le Moulec, S; Ravaud, A | 1 |
| Accardo, G; Avenia, N; Castaldo, F; Colantuoni, V; Conzo, G; Di Donna, C; Esposito, D; Gambardella, C; Giugliano, D; Mazzella, M; Pasquali, D; Polistena, A | 1 |
| Hedayati, M; Rajabi, S | 1 |
| Hadoux, J; Schlumberger, M | 1 |
| Akshintala, S; Balis, FM; Derse-Anthony, C; Dombi, E; Fox, E; Glod, JW; Kapustina, O; Kraft, IL; Lei, H; Lodish, M; Meltzer, PS; Merino, MJ; Shern, JF; Steinberg, SM; Waguespack, SG; Widemann, BC; Zhu, Y | 1 |
| Gao, B; Guo, L; Hao, S; Jiang, Y; Luo, D; Tian, W; Yan, J; Zhang, S; Zhang, X | 1 |
| Droeser, R; Kouraklis, G; Patsouris, E; Tampaki, EC; Tampakis, A | 1 |
| Baple, EL; Brooke, A; Derse-Anthony, C; Glod, J; Newbold, K; Osborne, N; Sturley, R; Thomas, N; Vaidya, B | 1 |
| Antonelli, A; Baldini, E; Bocci, G; Di Desidero, T; Elia, G; Fallahi, P; Ferrari, SM; Fioravanti, A; La Motta, C; Materazzi, G; Miccoli, P; Orlandi, P; Paparo, SR; Patrizio, A; Piaggi, S; Ragusa, F; Ruffilli, I; Ulisse, S | 1 |
| Imamura, Y; Matsuda, S; Sano, K; Umeda, Y; Yoshida, H; Yoshimura, H | 1 |
| Chi, WM; Hsieh, WS; Hsu, KW; Huang, LC; Lee, AW; Lee, CH; Lin, CL; Lin, CY; Liu, WN; Tam, KW; Yang, JM | 1 |
| Bumrah, C; Cote, GJ; Giordano, TJ; Knippler, CM; Miles, W; Ringel, MD; Saji, M; Valenciaga, A; Yilmaz, AS; Yu, L; Zhang, X | 1 |
| Balasubramaniam, S; Del Rivero, J; Edgerly, M; Fojo, T; Gramza, AW; Madan, RA; Ward, J | 1 |
| MacGregor, FB; Milner, TD; Reed, N; Ronghe, M; Shaikh, MG | 1 |
| Bauer, J; Grimm, D; Grosse, J; Infanger, M; Kopp, S; Krüger, M; Milling, RV; Wehland, M | 1 |
| Colombo, C; De Leo, S; Di Stefano, M; Fugazzola, L; Persani, L; Vannucchi, G | 1 |
| Choi, MG; Ihm, SH; Kang, JG; Kim, CS; Kim, SH; Lee, SJ | 2 |
| Dedecjus, M; Druce, M; Elisei, R; Gagel, RF; Hu, MI; Kapiteijn, E; Krajewska, J; Locati, L; Pacini, F; Popovtzer, A; Weiss, R | 1 |
| Abelleira, E; Bueno, F; Jerkovich, F; Pitoia, F; Schmidt, A | 1 |
| Balasubramanian, S; Carroll, C; Hamilton, J; Kaltenthaler, E; Moss, L; Tappenden, P; Wadsley, J; Wong, R | 1 |
| Britt, CJ; Russell, JO | 1 |
| Qiu, XY; Yin, Y; Zhang, B; Zhang, YH | 1 |
| Cunnane, ME; Randolph, GW; Ross, DS; Sadow, PM; Wirth, LJ | 1 |
| Burttet, LM; Cerski, MR; Dora, JM; Maia, AL; Scheffel, RS; Siqueira, DR | 1 |
| Park, JI; Starenki, D | 1 |
| Monneret, C | 1 |
| Antoun, S; Baracos, VE; Baudin, E; Borget, I; Broutin, S; Deroussent, A; Leboulleux, S; Massicotte, MH; Paci, A; Schlumberger, M | 1 |
| Frasca, F; Gianì, F; Lotta, S; Messina, RL; Nicolosi, ML; Regalbuto, C; Vella, V; Vigneri, P; Vigneri, R | 1 |
| Durante, C; Filetti, S; Paciaroni, A; Plasmati, K; Trulli, F | 1 |
| Banaszynski, ME; Kolesar, JM; Ton, GN | 1 |
| Aikin, A; Balis, FM; Chuk, MK; Dombi, E; Fox, E; Lodish, M; Marcus, L; Merino, MJ; Steinberg, SM; Wells, SA; Whitcomb, PO; Widemann, BC | 1 |
| Bartsch, DK; Doll, D; Greene, BH; Hoffmann, S; Khoruzhyk, M; Ramaswamy, A; Roth, S; Wunderlich, A | 1 |
| Bedard, PL; Castonguay, V; Chen, EX; Chen, H; Chen, Z; Clarke, B; Cohen, B; Hirte, HW; Hotte, SJ; Ivy, SP; Kamel-Reid, S; Liu, G; McGarrity, A; Oza, AM; Razak, AR; Reedijk, M; Sahebjam, S; Siu, LL; Wang, L; Zhang, T; Zhang, WJ | 1 |
| Higashiyama, S; Hosoi, H; Masui, T; Matsuura, N; Ota, I; Yane, K | 1 |
| Baudry, C; Groussin, L; Paepegaey, AC | 1 |
| Postel-Vinay, S; Schlumberger, M; Soria, JC | 1 |
| Cagan, RL; Das, TK | 1 |
| Chen, Z; Chowdry, RP; Khuri, FR; Kim, S; Owonikoko, TK; Saba, NF; Shin, DM | 1 |
| Capdevila, J; Filetti, S; Grande, E; Kreissl, MC; Newbold, K; Reinisch, W; Robert, C; Schlumberger, M; Tolstrup, LK; Zamorano, JL | 1 |
| Bidart, JM; Broutin, S; Caillou, B; Commo, F; De Koning, L; Dubois, T; Dupuy, C; Lacroix, L; Marty-Prouvost, B; Ryan, AJ; Schlumberger, M; Talbot, M | 1 |
| Alghamdi, W; Cooper, MR; Shaheen, DJ; Steinberg, M; Yi, SY | 1 |
| Cohen, MS; Sim, MW | 1 |
| Baudin, E; Borson-Chazot, F; Hescot, S; Lombès, M | 1 |
| Baudin, E; Bonichon, F; Borget, I; Brassard, M; Chougnet, CN; Claude-Desroches, M; de la Fouchardière, C; Do Cao, C; Giraudet, AL; Leboulleux, S; Massicotte, MH; Schlumberger, M | 1 |
| Anagnostis, P; Karras, S; Krassas, GE | 1 |
| Allolio, B; Buck, AK; Germer, CT; Lorenz, U; Ritter, CO; Wiegering, A | 1 |
| Balis, FM; Derdak, J; Fox, E; Kebebew, E; Lodish, MB; Nella, AA; Quezado, MM; Stratakis, CA; Whitcomb, PO; Widemann, BC | 1 |
| Camacho, D; Kumarasamy, V; Shin, YJ; Sun, D | 1 |
| Ito, K; Sugino, K; Takami, H | 1 |
| El-Shentenawy, A; Mohammed, AA | 1 |
| Cohen, PR; Jalalat, SZ | 1 |
| Caro-Gutiérrez, D; Floristán Muruzábal, MU; Franco, AP; Gómez de la Fuente, E; López Estebaranz, JL | 1 |
| Cabanillas, ME; Hu, MI; Jimenez, C | 1 |
| Colao, A; Faggiano, A; Marotta, V; Sciammarella, C; Vitale, M | 1 |
| Baudin, E; Chougnet, CN; Leboulleux, S; Schlumberger, M | 1 |
| Jarzab, B; Krajewska, J | 1 |
| Bardet, S; Bonichon, F; Borget, I; Chauffert, B; Chougnet, CN; Criniere, L; de la Fouchardiere, C; Drui, D; Leboulleux, S; Niccoli, P; Rohmer, V; Schlumberger, M; Schneegans, O; Schvartz, C; Zanetta, S | 1 |
| Curry, JL; Goldstein, J; Patel, AB; Piha-Paul, S; Subbiah, V | 1 |
| Boufraqech, M; Boxer, MB; Copland, JA; Davis, S; Kebebew, E; Kiefer, JA; Li, Z; Mehta, A; Shen, M; Smallridge, RC; Tian, Z; Wang, J; Yu, Z; Zhang, L; Zhang, Y | 1 |
| Karedan, T; Perez, CA; Wang, E | 1 |
| Fassnacht, M; Kreissl, MC; Mueller, SP | 1 |
| Antonelli, A; Benvenga, S; Di Bari, F; Fallahi, P; Ferrari, SM; Materazzi, G; Miccoli, P; Spisni, R | 1 |
| Alessandrini, S; Baldini, E; Catania, A; Coccaro, C; D'Armiento, M; Filippini, A; Morrone, S; Prinzi, N; Rendina, R; Sorrenti, S; Tuccilli, C; Ulisse, S | 1 |
| Bueno, F; Cross, G; Lucas, S; Pitoia, F; Schmidt, A | 1 |
| Covell, LL; Ganti, AK | 1 |
| Bradshaw, N; Davidson, R; MacGregor, FB; Narayanan, VK; Reed, N; Ronghe, M; Shaikh, MG; Welbury, R | 1 |
| Bandaru, S; Dunna, NR; Girdhar, A; Hussain, T; Kandula, V; Nayarisseri, A; Pudutha, A | 1 |
| Buck, AK; Grelle, I; Hänscheid, H; Herrmann, K; Higuchi, T; Lapa, C; Lückerath, K; Muegge, DO; Reiners, C; Schmid, JS; Werner, RA | 1 |
| Hadoux, J; Pacini, F; Schlumberger, M; Tuttle, RM | 1 |
| Cho, H; Choi, S; Kim, ND; Kwak, Y; Sim, T; Yoon, H | 1 |
| Beckmann, L; Bender, R; Lange, S | 1 |
| Boufraqech, M; Kebebew, E; Lake, R; Zhang, L | 1 |
| Barbry, P; Belléannée, G; Blanck, O; Bonnetaud, C; Bordone, O; Bozec, A; Brest, P; Butori, C; Catargi, B; Guevara, N; Hénaoui, IS; Hofman, P; Hofman, V; Ilie, M; Lassalle, S; Lemaire, G; Long, E; Mari, B; Patey, M; Peyrottes, I; Popa, A; Sadoul, JL; Santini, J; Tissier, F; Trouette, H; Vielh, P; Zangari, J | 1 |
| Ali, SM; Busaidy, NL; Chmielecki, J; Elvin, JA; Erlich, RL; Heilmann, AM; Khan, SA; Lipson, D; Miller, VA; Murthy, R; Nangia, C; Ross, JS; Shah, MH; Sherman, SI; Stephens, PJ; Subbiah, I; Subbiah, V; Sun, JX; Vergilio, JA; Wang, K; Yelensky, R | 1 |
| Badziong, J; Führer, D; Herold, T; Schmid, KW; Tiedje, V; Ting, S; Walter, RF; Worm, K; Zwanziger, D | 1 |
| Learoyd, DL; Robinson, BG; Tsang, VH | 1 |
| Chabre, O; Dupuis, C; Durand, C; Piolat, C; Plantaz, D; Segura, D | 1 |
| Antonelli, A; Baldini, E; Biricotti, M; Fallahi, P; Ferrari, SM; Materazzi, G; Miccoli, P; Ulisse, S | 1 |
| Chen, AY; Ernani, V; Kumar, M; Owonikoko, TK | 1 |
| Horiuchi, K; Ito, Y; Komoda, M; Okamoto, T; Rito, K; Takahashi, S; Todo, T; Tomomatsu, J; Tsuji, A; Uchino, K | 1 |
| Alifano, M; Bienvenu-Perrard, M; Bricaire, L; Burnichon, N; Cochand-Priollet, B; Groussin, L; Lahlou, N; Louiset, E; Paepegaey, AC; Sarfati, PO | 1 |
| Bongarzone, I; Cassinelli, G; Cremona, M; Cuccuru, G; Gorla, L; Lanzi, C; Miccichè, F; Mondellini, P; Pierotti, MA | 1 |
| Ikeda, K; Itoh, S; Matsumoto, F; Ohba, S | 1 |
| Altaha, R; Hogan, T; Williams, HJ | 1 |
| French, JD; Grzywa, RL; Haugen, BR; Kerege, AA; Schweppe, RE; Sharma, V | 1 |
| Campiglia, P; De Falco, V; Fenzi, G; Illario, M; Monaco, S; Pastore, L; Rossi, G; Rusciano, MR; Salzano, M; Santoro, M; Sapio, MR; Vitale, M | 1 |
| Sherman, SI | 2 |
| Gagel, RF; Gosnell, JE; Krebs, A; Moley, J; Pfister, D; Schlumberger, M; Skinner, M; Sosa, JA; Vasselli, J; Wells, SA | 1 |
| Moretti, S; Puxeddu, E; Romagnoli, S; Voce, P | 1 |
| Cignarelli, M; Fabiano, A; La Macchia, O; Landriscina, M; Maddalena, F; Piscazzi, A | 1 |
| Haddad, R; Krebs, A; Paz-Ares, L; Robinson, BG; Vasselli, J | 1 |
| Chen, MC; Chi, CW; Ho, LL; Kan, SF; Lee, CH; Lin, LC; Pu, HF; Wang, PS; Wang, SW; Yu, CH | 1 |
| Carlomagno, F; Chiappetta, G; Ciardiello, F; Coluzzi, S; De Falco, V; Fagin, JA; Ryan, AJ; Santoro, M; Tamburrino, A; Tortora, G; Troncone, G; Vitagliano, D | 1 |
| Abagnale, A; Barbato, S; Botta, G; Chieffi, P; Libertini, S; Passaro, C; Portella, G | 1 |
| Bankson, JA; Chen, Y; Frederick, MJ; Galer, CE; Gule, MK; Henderson, YC; Jasser, SA; Lai, SY; Milas, ZL; Myers, JN; Sano, D; Schwartz, DL; Zhao, M; Zhou, G | 1 |
| Benz, MR; Bockisch, A; Czernin, J; Damoiseaux, RD; Hartung, V; Hildebrandt, IJ; Laing, RE; Phelps, ME; Walter, MA; Weber, WA | 1 |
| Takami, HE | 1 |
| Masago, K; Mishima, M; Miura, M; Togashi, Y; Toyama, Y | 1 |
| Arango, BA; Cohen, EE; Perez, CA; Raez, LE; Santos, ES | 1 |
| Fassnacht, M; Kreissl, MC; Schott, M; Spitzweg, C; Willhauck, MJ | 1 |
| Hu, MI | 1 |
| Hashimoto, K; Komune, S; Nakano, T; Nakashima, T; Oda, Y; Oyama, M; Shiratsuchi, H; Tamiya, S; Yamamoto, H | 1 |
| Baudin, E; Borget, I; Brailly-Tabard, S; Brassard, M; Chanson, P; Leboulleux, S; Neraud, B; Salenave, S; Schlumberger, M; Trabado, S; Young, J | 1 |
| Commander, H; Perry, C; Whiteside, G | 1 |
| Fujiwara, K; Kiura, K; Kudo, K; Matsuo, K; Mizuta, M; Rai, K; Sato, T; Tsushima, M; Yamadori, I; Yonei, T | 1 |
| Baudin, E; Dralle, H; Elisei, R; Fagin, JA; Gagel, RF; Jarzab, B; Langmuir, P; Read, J; Robinson, BG; Ryan, AJ; Santoro, M; Schlumberger, MJ; Vasselli, JR; Wells, SA | 1 |
| Rischin, D; Solomon, B | 1 |
| Koch, L | 1 |
| Langmuir, PB; Yver, A | 1 |
| Houvras, Y | 1 |
| Benoit, A; Cho, TH; de la Fouchardière, C; Derbel, O; Duplomb, S; Mechtouff-Cimarelli, L; Peix, JL | 1 |
| Almeida, MQ; Hoff, AO | 1 |
| Damse, A; Lacouture, ME; Rosen, AC; Sherman, E; Wu, S | 1 |
| Pashankar, FD; Rapkin, L | 1 |
| Barbet, J; Chatal, JF; Goldenberg, DM; Kraeber-Bodéré, F | 1 |
| Baudin, E; Chougnet, C; Leboulleux, S; Massicotte, MH; Nascimento, CL; Schlumberger, M | 1 |
| Balakrishnan, S; Booth, B; Chattopadhyay, S; Dorsam, R; Duan, J; Garnett, C; Gehrke, B; Ghosh, D; Ibrahim, A; Justice, R; Kim, G; Liu, Q; Maher, VE; Marathe, A; Miksinski, SP; Moon, YJ; Murgo, A; Pazdur, R; Sarker, H; Skarupa, L; Song, P; Tang, S; Thornton, K; Verbois, L; Wilson, W; Zhu, H | 1 |
| Chen, J; Cui, IH; Gong, Y; Jin, Y; Tang, C; Wu, X; Xu, Z; Zhang, X; Zhang, Y | 1 |
| Frampton, JE | 1 |
| Aide, N; Bardet, S; Crouzeix, G; Michels, JJ; Sevin, E; Vaur, D | 1 |
| Bible, KC | 1 |
| Awada, A; Bastholt, L; Bonichon, F; de la Fouchardiere, C; Gómez, JM; Krause, T; Leboulleux, S; Leenhardt, L; Licour, M; Schlumberger, MJ; Soufflet, C; Tennvall, J | 1 |
| Frampton, JE; Keating, GM; Lyseng-Williamson, KA | 1 |
| Furberg, CD; Moore, TJ | 1 |
| Baum, RP; Briest, F; Grabowski, P; Hörsch, D; Kulkarni, HR; Zaknun, JJ; Zeitz, M | 1 |
| Campbell, MJ; Gosnell, J; Seib, CD | 1 |
| Chau, NG; Haddad, RI | 1 |
| Arnault, JP; Baudin, E; Brassard, M; Giacchero, D; Maksimovic, L; Mateus, C; Ramacciotti, C; Robert, C; Schlumberger, M; Tomasic, G; Wechsler, J | 1 |
| Carlomagno, F; Ciardiello, F; Fontanini, G; Fusco, A; Guida, T; Ryan, AJ; Santoro, M; Tortora, G; Vecchio, G; Vitagliano, D | 1 |
| Carlomagno, F; Fusco, A; Hershman, JM; Melillo, RM; Motti, ML; Nikiforov, YE; Nikiforova, MN; Ryan, AJ; Santoro, M; Viglietto, G; Vitagliano, D | 1 |
| Anaganti, S; Billaud, M; Carlomagno, F; Fusco, A; Guida, T; Ryan, AJ; Santoro, M; Vecchio, G | 1 |
| Bekele, BN; Doan, D; El-Naggar, AK; Holsinger, FC; Jasser, SA; Kim, S; Mandal, M; McMurphy, AB; Myers, JN; Schiff, BA; Sherman, SI; Yeung, SC; Yigitbasi, OG; Younes, MN; Zhou, G | 1 |
| Carlomagno, F; Santoro, M | 1 |
| Hirakawa, K; Ishikawa, T; Nobuhara, Y; Ogisawa, K; Onoda, N; Takashima, T; Yamasaki, M; Yamashita, Y | 1 |
| Cagan, R; Ryan, A; Vidal, M; Wells, S | 1 |
| Ikeda, M; Kurebayashi, J; Okubo, S; Otsuki, T; Sonoo, H; Tanaka, K; Yamamoto, Y | 1 |
| Cazzaniga, S; Gambacorti-Passerini, C; Mologni, L; Papinutto, E; Sala, E | 1 |
| Burchert, A; Dietrich, C; Gläser, S; Hoffmann, S; Lingelbach, S; Müller, H; Rothmund, M; Wunderlich, A; Zielke, A | 1 |
| Clark, OH; Duh, QY; Park, JW; Rougier, JP; Werb, Z; Wong, M; Yeh, MW | 1 |
| Ahlman, H; Bernhardt, P; Jansson, S; Johanson, V; Kölby, L; Nilsson, O; Persson, F; Stenman, G; Stridsberg, M; Swärd, C; Wängberg, B | 1 |
| Fooshee, D; Gomez-Rivera, F; Jasser, SA; Kim, S; Myers, JN; Santillan-Gomez, AA; Younes, MN; Zhao, M | 1 |
| Aguilera, J; Chang, C; Chen, JS; Lopez, JP; Ongkeko, WM; Pardo, FS; Wang-Rodriguez, J | 1 |
| Clark, JR; Daniels, GH; Evans, T; Fidias, PH; Gurubhagavatula, S; Haddad, RI; Heist, RS; Lynch, TJ; Pennell, NA; Ross, DS; Temel, JS; Wirth, LJ | 1 |
| Aguilera, J; Chang, CY; Lopez, JP; Ongkeko, WM; Pardo, FS; Sneh, G; Wang-Rodriguez, J; Yu, MA | 1 |
| Bergström, JD; Heldin, NE; Westermark, B | 1 |
47 review(s) available for quinazolines and Cancer of the Thyroid
| Article | Year |
|---|---|
Long-term follow-up and safety of vandetanib for advanced medullary thyroid cancer.
Topics: Acute Disease; Adult; Antineoplastic Agents; Carcinoma, Neuroendocrine; Disease-Free Survival; Follow-Up Studies; France; Humans; Pancreatitis; Piperidines; Quinazolines; Thyroid Neoplasms | 2021 |
Comparative efficacy and safety of tyrosine kinase inhibitors for thyroid cancer: a systematic review and meta-analysis.
Topics: Antineoplastic Agents; Humans; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Quinazolines; Quinolines; Sorafenib; Thyroid Neoplasms; Treatment Outcome | 2020 |
CD30+ lymphoproliferative disorder in a patient with metastatic papillary thyroid carcinoma.
Topics: Aged; Carcinoma; Carcinoma, Papillary; Humans; Immunohistochemistry; Ki-1 Antigen; Lymphoma, Large-Cell, Anaplastic; Lymphoproliferative Disorders; Male; Neoplasms, Multiple Primary; Piperidines; Quinazolines; Skin Neoplasms; Thoracic Wall; Thyroid Cancer, Papillary; Thyroid Neoplasms | 2016 |
Genetics of medullary thyroid cancer: An overview.
Topics: Anilides; Carcinoma, Medullary; Codon; Exons; Humans; Male; Middle Aged; Multiple Endocrine Neoplasia Type 2a; Mutation; Piperidines; Polymorphism, Genetic; Proto-Oncogene Mas; Proto-Oncogene Proteins c-ret; Pyridines; Quinazolines; Thyroid Neoplasms; Thyroidectomy | 2017 |
Medullary Thyroid Cancer: Clinical Characteristics and New Insights into Therapeutic Strategies Targeting Tyrosine Kinases.
Topics: Anilides; Antineoplastic Agents; Carcinoma, Neuroendocrine; Clinical Trials as Topic; High-Throughput Nucleotide Sequencing; Humans; Molecular Targeted Therapy; Mutation; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Quinazolines; Thyroid Neoplasms | 2017 |
Chemotherapy and tyrosine-kinase inhibitors for medullary thyroid cancer.
Topics: Anilides; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Neuroendocrine; Disease-Free Survival; Humans; Molecular Targeted Therapy; Neoplasm Metastasis; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Quinazolines; Thyroid Neoplasms | 2017 |
Pazopanib, Cabozantinib, and Vandetanib in the Treatment of Progressive Medullary Thyroid Cancer with a Special Focus on the Adverse Effects on Hypertension.
Topics: Anilides; Carcinoma, Neuroendocrine; Cardiotoxicity; Humans; Hypertension; Indazoles; Piperidines; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Quinazolines; Sulfonamides; Thyroid Neoplasms | 2018 |
Cabozantinib and vandetanib for unresectable locally advanced or metastatic medullary thyroid cancer: a systematic review and economic model.
Topics: Anilides; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Neuroendocrine; Cost-Benefit Analysis; England; Humans; Models, Economic; Piperidines; Pyridines; Quality-Adjusted Life Years; Quinazolines; Technology Assessment, Biomedical; Thyroid Neoplasms | 2019 |
[Four new drugs on the market: abiraterone, belatacept, vandetanib and fidaxomycine].
Topics: Abatacept; Aminoglycosides; Androstenes; Androstenols; Anti-Bacterial Agents; Antineoplastic Agents; Clostridioides difficile; Clostridium Infections; Enzyme Inhibitors; Fidaxomicin; Humans; Immunoconjugates; Immunosuppressive Agents; Male; Piperidines; Prostatic Neoplasms; Quinazolines; Thyroid Neoplasms | 2013 |
Vandetanib: opening a new treatment practice in advanced medullary thyroid carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Neuroendocrine; Disease Progression; Drugs, Investigational; Humans; Medical Oncology; Piperidines; Professional Practice; Quinazolines; Thyroid Neoplasms; Treatment Outcome | 2013 |
Vandetanib: a novel targeted therapy for the treatment of metastatic or locally advanced medullary thyroid cancer.
Topics: Antineoplastic Agents; Carcinoma, Neuroendocrine; Clinical Trials as Topic; Disease-Free Survival; ErbB Receptors; Fees, Pharmaceutical; Humans; Piperidines; Quinazolines; Thyroid Neoplasms | 2013 |
A Drosophila approach to thyroid cancer therapeutics.
Topics: Animals; Antineoplastic Agents; Disease Models, Animal; Drosophila; Drug Evaluation, Preclinical; Humans; Piperidines; Proto-Oncogene Proteins c-ret; Quinazolines; Thyroid Neoplasms | 2013 |
Vandetanib in advanced medullary thyroid cancer: review of adverse event management strategies.
Topics: Carcinoma, Neuroendocrine; Cardiovascular Diseases; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Eruptions; Drug-Related Side Effects and Adverse Reactions; Female; Gastrointestinal Diseases; Humans; Male; Neoplasm Invasiveness; Neoplasm Staging; Patient Selection; Piperidines; Prognosis; Quinazolines; Risk Assessment; Thyroid Neoplasms; Treatment Outcome | 2013 |
Vandetanib for the treatment of medullary thyroid carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Medullary; Carcinoma, Neuroendocrine; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Disease-Free Survival; Drug Interactions; Drug Labeling; Humans; Neoplasm Metastasis; Piperidines; Quinazolines; Randomized Controlled Trials as Topic; Thyroid Neoplasms | 2014 |
The discovery and development of vandetanib for the treatment of thyroid cancer.
Topics: Disease-Free Survival; Drug Discovery; Humans; Piperidines; Quinazolines; Thyroid Neoplasms | 2014 |
[Targeted therapies, prognostic and predictive factors in endocrine oncology].
Topics: Antineoplastic Agents; Carcinoma, Neuroendocrine; Clinical Trials, Phase III as Topic; Disease-Free Survival; Endocrine Gland Neoplasms; Everolimus; Humans; Indoles; Molecular Targeted Therapy; Neuroendocrine Tumors; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Piperidines; Prognosis; Pyrroles; Quinazolines; Sirolimus; Sorafenib; Sunitinib; Thyroid Neoplasms; Treatment Outcome | 2013 |
Vandetanib for the treatment of thyroid cancer: an update.
Topics: Animals; Carcinoma, Neuroendocrine; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Disease Models, Animal; Drug Evaluation, Preclinical; Epidermal Growth Factor; Humans; Piperidines; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Thyroid Neoplasms; Transfection; Treatment Outcome; Vascular Endothelial Growth Factor Receptor-2 | 2014 |
Development of molecular targeted drugs for advanced thyroid cancer in Japan.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Humans; Japan; Molecular Targeted Therapy; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Piperidines; Quinazolines; Quinolines; Sorafenib; Thyroid Neoplasms | 2014 |
Advanced thyroid cancers: new era of treatment.
Topics: Anilides; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Differentiation; Cell Proliferation; ErbB Receptors; Genetic Therapy; Histone Deacetylase Inhibitors; Humans; Immunotherapy; Lithium; Molecular Targeted Therapy; Piperidines; Protein Kinase Inhibitors; Pyrazines; Pyridines; Quinazolines; Stilbenes; Thalidomide; Thyroid Neoplasms | 2014 |
The evolving field of kinase inhibitors in thyroid cancer.
Topics: Angiogenesis Inhibitors; Anilides; Antineoplastic Agents; Humans; Niacinamide; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Pyridines; Quinazolines; Quinolines; Sorafenib; Thyroid Neoplasms | 2015 |
[Vandetanib, in the management of patients with locally advanced or metastatic medullary thyroid carcinomas].
Topics: Antineoplastic Agents; Carcinoma, Medullary; Carcinoma, Neuroendocrine; Humans; Piperidines; Proto-Oncogene Proteins c-ret; Quinazolines; Rare Diseases; Thyroid Neoplasms | 2014 |
Novel therapies for thyroid cancer.
Topics: Anilides; Antineoplastic Agents; Clinical Trials as Topic; Diarrhea; Humans; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Pyridines; Quinazolines; Quinolines; Receptors, Vascular Endothelial Growth Factor; Thyroid Neoplasms | 2014 |
New insights in the treatment of radioiodine refractory differentiated thyroid carcinomas: to lenvatinib and beyond.
Topics: Antineoplastic Agents; Clinical Trials, Phase II as Topic; Humans; Iodine Radioisotopes; Mutation; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Quinazolines; Quinolines; Signal Transduction; Sorafenib; Thyroid Neoplasms; Treatment Failure | 2015 |
Systemic treatment of advanced differentiated and medullary thyroid cancer. Overview and practical aspects.
Topics: Anilides; Antineoplastic Agents; Drug Monitoring; Evidence-Based Medicine; Humans; Piperidines; Protein-Tyrosine Kinases; Pyridines; Quinazolines; Thyroid Neoplasms; Tomography, Emission-Computed; Treatment Outcome | 2015 |
Selective use of vandetanib in the treatment of thyroid cancer.
Topics: Animals; Antineoplastic Agents; Disease-Free Survival; Humans; Molecular Targeted Therapy; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-ret; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Thyroid Neoplasms; Treatment Outcome | 2015 |
Treatment of advanced thyroid cancer: role of molecularly targeted therapies.
Topics: Anilides; Antineoplastic Agents; Axitinib; Carcinoma, Neuroendocrine; DNA Mutational Analysis; Drug Approval; Humans; Imidazoles; Indazoles; Indoles; MAP Kinase Signaling System; Molecular Targeted Therapy; Niacinamide; Oligonucleotides; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Piperidines; Proto-Oncogene Proteins c-ret; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Quinolines; Sorafenib; Sulfonamides; Sunitinib; Thyroid Neoplasms; United States; United States Food and Drug Administration; Vascular Endothelial Growth Factor A | 2015 |
Management of advanced medullary thyroid cancer.
Topics: Anilides; Antineoplastic Agents; Biomarkers; Calcitonin; Carcinoembryonic Antigen; Carcinoma, Neuroendocrine; Disease Progression; Disease-Free Survival; Humans; Molecular Targeted Therapy; Piperidines; Pyridines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Thyroid Neoplasms; Treatment Outcome | 2016 |
The safety of vandetanib for the treatment of thyroid cancer.
Topics: Animals; Antineoplastic Agents; Carcinoma, Neuroendocrine; Disease-Free Survival; Humans; Piperidines; Protein Kinase Inhibitors; Quality of Life; Quinazolines; Survival Rate; Thyroid Neoplasms | 2016 |
The safety and efficacy of vandetanib in the treatment of progressive medullary thyroid cancer.
Topics: Adolescent; Adult; Animals; Antineoplastic Agents; Carcinoma, Neuroendocrine; Child; Disease Progression; Disease-Free Survival; Humans; Piperidines; Protein Kinase Inhibitors; Quality of Life; Quinazolines; Thyroid Neoplasms | 2016 |
Systemic treatment and management approaches for medullary thyroid cancer.
Topics: Anilides; Antineoplastic Agents; Carcinoma, Neuroendocrine; Chemotherapy, Adjuvant; Genotype; Humans; Molecular Targeted Therapy; Phenotype; Piperidines; Proto-Oncogene Mas; Proto-Oncogene Proteins c-ret; Pyridines; Quinazolines; Receptors, Fibroblast Growth Factor; Thyroid Neoplasms; Thyroidectomy; Vascular Endothelial Growth Factor Receptor-2 | 2016 |
Tyrosine kinase inhibitors and the thyroid.
Topics: Axitinib; Benzenesulfonates; Clinical Trials as Topic; Gefitinib; Humans; Imidazoles; Indazoles; Indoles; Niacinamide; Oligonucleotides; Pharmaceutical Preparations; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins B-raf; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sulfonamides; Sunitinib; Thyroid Gland; Thyroid Neoplasms | 2009 |
Targeted molecular therapies in thyroid carcinoma.
Topics: Antineoplastic Agents; Axitinib; Benzenesulfonates; Carcinoma, Medullary; Carcinoma, Papillary; Humans; Imidazoles; Indazoles; Indoles; Niacinamide; Oligonucleotides; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Pyridines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Thyroid Neoplasms | 2009 |
Current status of molecularly targeted drugs for the treatment of advanced thyroid cancer.
Topics: Anilides; Benzenesulfonates; Disease Progression; Humans; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Pyridines; Quinazolines; Sorafenib; Thyroid Neoplasms | 2011 |
Novel molecular targeted therapies for refractory thyroid cancer.
Topics: Angiogenesis Inhibitors; Anilides; Antineoplastic Agents; Axitinib; Benzamides; Benzenesulfonates; Benzoquinones; Bibenzyls; Boronic Acids; Bortezomib; Depsipeptides; ErbB Receptors; Gefitinib; Histone Deacetylase Inhibitors; HSP90 Heat-Shock Proteins; Humans; Hydroxamic Acids; Imatinib Mesylate; Imidazoles; Indazoles; Indoles; Lactams, Macrocyclic; Lenalidomide; Niacinamide; Oligonucleotides; Phenylurea Compounds; Piperazines; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrazines; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Quinolines; Receptor Protein-Tyrosine Kinases; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sulfonamides; Sunitinib; Thalidomide; Thyroid Neoplasms; Valproic Acid; Vorinostat | 2012 |
Vandetanib for the treatment of thyroid cancer.
Topics: Animals; Antineoplastic Agents; Clinical Trials as Topic; ErbB Receptors; Humans; Piperidines; Quinazolines; Thyroid Neoplasms; Treatment Outcome | 2012 |
Vandetanib (Caprelsa) for medullary thyroid cancer.
Topics: Carcinoma, Neuroendocrine; Drug Costs; Drug Interactions; Humans; Piperidines; Quinazolines; Randomized Controlled Trials as Topic; Thyroid Neoplasms | 2012 |
Recent advances in the molecular pathogenesis and targeted therapies of medullary thyroid carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Neuroendocrine; Clinical Trials, Phase III as Topic; Female; Humans; Male; Molecular Targeted Therapy; Mutation; Piperidines; Prognosis; Quinazolines; Signal Transduction; Thyroid Neoplasms; Time Factors; TOR Serine-Threonine Kinases | 2012 |
Risk of rash in cancer patients treated with vandetanib: systematic review and meta-analysis.
Topics: Antineoplastic Agents; Breast Neoplasms; Carcinoma, Neuroendocrine; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Eruptions; ErbB Receptors; Female; Humans; Incidence; Lung Neoplasms; Male; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-ret; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Risk; Severity of Illness Index; Small Cell Lung Carcinoma; Thyroid Neoplasms | 2012 |
Management of thyroid carcinoma in children and young adults.
Topics: Adolescent; Age Factors; Child; Child, Preschool; Female; Humans; Iodine Isotopes; Male; Piperidines; Quinazolines; Thyroid Neoplasms; Thyrotropin; Young Adult | 2012 |
Kinase inhibitors for advanced medullary thyroid carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Medullary; Carcinoma, Neuroendocrine; Clinical Trials as Topic; Humans; Molecular Targeted Therapy; Patient Selection; Piperidines; Protein Kinase Inhibitors; Quinazolines; Thyroid Neoplasms | 2012 |
Addition of vandetanib to chemotherapy in advanced solid cancers: a meta-analysis.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Humans; Lung Neoplasms; Neoplasms; Piperidines; Quinazolines; Thyroid Neoplasms; Treatment Outcome | 2012 |
Vandetanib: in medullary thyroid cancer.
Topics: Administration, Oral; Antineoplastic Agents; Carcinoma, Neuroendocrine; Disease-Free Survival; Humans; Molecular Structure; Neoplasm Metastasis; Piperidines; Protein-Tyrosine Kinases; Quinazolines; Randomized Controlled Trials as Topic; Thyroid Neoplasms | 2012 |
Vandetanib: a guide to its use in advanced medullary thyroid cancer.
Topics: Carcinoma, Neuroendocrine; Disease-Free Survival; Humans; Neoplasm Invasiveness; Neoplasm Metastasis; Piperidines; Practice Guidelines as Topic; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Thyroid Neoplasms | 2012 |
Vandetanib therapy in medullary thyroid cancer.
Topics: Animals; Antineoplastic Agents; Carcinoma, Neuroendocrine; Drug Interactions; ErbB Receptors; Humans; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Mas; Proto-Oncogene Proteins c-ret; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Thyroid Neoplasms | 2012 |
Vandetanib and the management of advanced medullary thyroid cancer.
Topics: Antineoplastic Agents; Carcinoma, Medullary; Clinical Trials as Topic; Humans; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Mas; Quinazolines; Thyroid Neoplasms | 2013 |
Vandetanib for the treatment of medullary thyroid cancer.
Topics: Antineoplastic Agents; Carcinoma, Neuroendocrine; Clinical Trials as Topic; Humans; Piperidines; Protein Kinase Inhibitors; Quinazolines; Thyroid Neoplasms; Treatment Outcome | 2013 |
Early clinical studies of novel therapies for thyroid cancers.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Axitinib; Benzamides; Benzenesulfonates; Carcinoma; Clinical Trials as Topic; Drug Delivery Systems; Gefitinib; Humans; Imatinib Mesylate; Imidazoles; Indazoles; Indoles; Niacinamide; Oligonucleotides; Phenylurea Compounds; Piperazines; Piperidines; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Quinazolines; Sorafenib; Thyroid Neoplasms | 2008 |
17 trial(s) available for quinazolines and Cancer of the Thyroid
| Article | Year |
|---|---|
Phase 3 Trial of Selpercatinib in Advanced
Topics: Antineoplastic Agents; Disease Progression; Humans; Piperidines; Proto-Oncogene Proteins c-ret; Pyridines; Quinazolines; Thyroid Neoplasms | 2023 |
Phase I/II Trial of Vandetanib and Bortezomib in Adults with Locally Advanced or Metastatic Medullary Thyroid Cancer.
Topics: Antineoplastic Agents; Bortezomib; Carcinoma, Neuroendocrine; Female; Humans; Male; Piperidines; Proto-Oncogene Mas; Quinazolines; Thyroid Neoplasms | 2019 |
Safety and efficacy of two starting doses of vandetanib in advanced medullary thyroid cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Carcinoma, Neuroendocrine; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Male; Middle Aged; Piperidines; Protein Kinase Inhibitors; Quinazolines; Thyroid Neoplasms; Young Adult | 2019 |
Body composition variation and impact of low skeletal muscle mass in patients with advanced medullary thyroid carcinoma treated with vandetanib: results from a placebo-controlled study.
Topics: Adult; Aged; Body Composition; Carcinoma, Neuroendocrine; Cross-Over Studies; Female; Humans; Male; Middle Aged; Muscle, Skeletal; Piperidines; Protein Kinase Inhibitors; Quinazolines; Thyroid Neoplasms | 2013 |
Vandetanib in children and adolescents with multiple endocrine neoplasia type 2B associated medullary thyroid carcinoma.
Topics: Adolescent; Carcinoma, Medullary; Carcinoma, Neuroendocrine; Child; Child, Preschool; Drug-Related Side Effects and Adverse Reactions; Gene Expression Regulation, Neoplastic; Germ-Line Mutation; Humans; Multiple Endocrine Neoplasia Type 2b; Neoplasm Metastasis; Neoplasm Recurrence, Local; Piperidines; Protein-Tyrosine Kinases; Proto-Oncogene Mas; Proto-Oncogene Proteins c-ret; Quinazolines; Thyroid Neoplasms | 2013 |
A phase I study of the combination of ro4929097 and cediranib in patients with advanced solid tumours (PJC-004/NCI 8503).
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzazepines; Breast Neoplasms; Carcinoma, Neuroendocrine; Carcinoma, Renal Cell; Colorectal Neoplasms; Female; Humans; Kidney Neoplasms; Leiomyosarcoma; Male; Middle Aged; Neoplasms; Quinazolines; Sarcoma, Endometrial Stromal; Thyroid Neoplasms; Treatment Outcome; Uterine Neoplasms; Young Adult | 2013 |
Clinical efficacy of targeted biologic agents as second-line therapy of advanced thyroid cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Neuroendocrine; Disease-Free Survival; Everolimus; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Piperidines; Quinazolines; Retrospective Studies; Sirolimus; Sorafenib; Thyroid Neoplasms; Treatment Outcome | 2013 |
Photoallergic reaction in a patient receiving vandetanib for metastatic follicular thyroid carcinoma: a case report.
Topics: Adenocarcinoma, Follicular; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Dermatitis, Photoallergic; Everolimus; Female; Humans; Middle Aged; Piperidines; Protein-Tyrosine Kinases; Quinazolines; Thyroid Neoplasms | 2015 |
SAFETY AND TOLERABILITY OF VANDETANIB IN JAPANESE PATIENTS WITH MEDULLARY THYROID CANCER: A PHASE I/II OPEN-LABEL STUDY.
Topics: Adult; Aged; Antineoplastic Agents; Asian People; Carcinoma, Neuroendocrine; Disease-Free Survival; ErbB Receptors; Female; Humans; Male; Middle Aged; Piperidines; Quinazolines; Thyroid Neoplasms; Treatment Outcome | 2017 |
Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Calcitonin; Carcinoembryonic Antigen; Carcinoma, Medullary; Disease-Free Survival; Drug Administration Schedule; Female; France; Genetic Predisposition to Disease; Germ-Line Mutation; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Pedigree; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Mas; Proto-Oncogene Proteins c-ret; Quinazolines; Risk Factors; Thyroid Neoplasms; Time Factors; Treatment Outcome; United States; Young Adult | 2010 |
Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer.
Topics: Adult; Aged; Antineoplastic Agents; Calcitonin; Carcinoembryonic Antigen; Carcinoma, Medullary; Codon; Double-Blind Method; Female; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Metastasis; Piperidines; Protein Kinase Inhibitors; Quinazolines; Thyroid Neoplasms; Tomography, X-Ray Computed; Young Adult | 2010 |
Endocrine effects of the tyrosine kinase inhibitor vandetanib in patients treated for thyroid cancer.
Topics: Adenocarcinoma, Follicular; Adenocarcinoma, Papillary; Adult; Aged; Aged, 80 and over; Blood Glucose; Calcium; Cross-Over Studies; Enzyme Inhibitors; ErbB Receptors; Female; Humans; Male; Middle Aged; Parathyroid Hormone; Piperidines; Proto-Oncogene Proteins c-ret; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Testosterone; Thyroid Neoplasms; Treatment Outcome; Vitamin D | 2011 |
Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial.
Topics: Carcinoma, Neuroendocrine; Disease Progression; Double-Blind Method; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Piperidines; Placebos; Quinazolines; Thyroid Neoplasms | 2012 |
Vandetanib for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease: U.S. Food and Drug Administration drug approval summary.
Topics: Carcinoma, Neuroendocrine; Disease-Free Survival; Drug Approval; Humans; Piperidines; Quinazolines; Thyroid Neoplasms; United States; United States Food and Drug Administration | 2012 |
Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial.
Topics: Adenocarcinoma, Follicular; Adolescent; Adult; Aged; Antineoplastic Agents; Bone Neoplasms; Carcinoma; Carcinoma, Papillary; Diarrhea; Disease-Free Survival; Double-Blind Method; Electrocardiography; ErbB Receptors; Female; Heart Conduction System; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Piperidines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Skin Neoplasms; Survival Analysis; Thyroid Cancer, Papillary; Thyroid Neoplasms; Young Adult | 2012 |
A new spectrum of skin toxic effects associated with the multikinase inhibitor vandetanib.
Topics: Adult; Aged; Aged, 80 and over; Female; Folliculitis; Hand-Foot Syndrome; Humans; Hyperpigmentation; Male; Middle Aged; Photosensitivity Disorders; Piperidines; Protein Kinase Inhibitors; Quinazolines; Thyroid Neoplasms | 2012 |
A phase II study of gefitinib in patients with advanced thyroid cancer.
Topics: Adenocarcinoma, Follicular; Adenoma, Oxyphilic; Aged; Antineoplastic Agents; Carcinoma, Medullary; Carcinoma, Papillary; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Male; Quinazolines; Severity of Illness Index; Thyroglobulin; Thyroid Neoplasms; Treatment Outcome | 2008 |
109 other study(ies) available for quinazolines and Cancer of the Thyroid
| Article | Year |
|---|---|
An Unusual Case of Hypopituitarism as an Adverse Effect of Vandetanib and Remission of Breast Metastases in a Patient with Medullary Thyroid Cancer.
Topics: Carcinoma, Neuroendocrine; Female; Humans; Hypopituitarism; Piperidines; Quinazolines; Thyroid Neoplasms | 2021 |
[Drug approval: Selpercatinib and pralsetinib - RET-altered thyroid cancer].
Topics: Anilides; Antineoplastic Agents; Carcinoma, Medullary; Drug Approval; Humans; Mutation; Phenylurea Compounds; Piperidines; Precision Medicine; Proto-Oncogene Proteins c-ret; Pyrazoles; Pyridines; Pyrimidines; Quinazolines; Quinolines; Thyroid Cancer, Papillary; Thyroid Neoplasms | 2021 |
Continued Discontinuation of TKI Treatment in Medullary Thyroid Carcinoma - Lessons From Individual Cases With Long-Term Follow-Up.
Topics: Adult; Carcinoma, Neuroendocrine; Drug-Related Side Effects and Adverse Reactions; Female; Follow-Up Studies; Humans; Male; Middle Aged; Piperidines; Prognosis; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Thyroid Neoplasms; Withholding Treatment; Young Adult | 2021 |
[Medullary thyroid carcinoma: current clinical progress].
Topics: Anilides; Antineoplastic Agents; Carcinoma, Neuroendocrine; Humans; Piperidines; Pyridines; Quinazolines; Thyroid Neoplasms | 2021 |
Disseminated medullary thyroid cancer - an alternative therapeutic approach.
Topics: Antineoplastic Agents; Carcinoma, Neuroendocrine; Humans; Piperidines; Quinazolines; Thyroid Neoplasms | 2022 |
Medullary thyroid cancer treated with vandetanib: predictors of a longer and durable response.
Topics: Adolescent; Adult; Aged; Carcinoma, Neuroendocrine; Female; Humans; Male; Middle Aged; Piperidines; Quinazolines; Thyroid Neoplasms; Young Adult | 2020 |
YAP confers resistance to vandetanib in medullary thyroid cancer.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antineoplastic Agents; Carcinoma, Neuroendocrine; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Female; Gene Silencing; Humans; Inhibitory Concentration 50; Mice; Mice, Nude; Mutation; Piperidines; Proto-Oncogene Proteins c-ret; Quinazolines; Signal Transduction; Thyroid Neoplasms; Transcription Factors; Xenograft Model Antitumor Assays; YAP-Signaling Proteins | 2020 |
Increased therapeutic effect on medullary thyroid cancer using a combination of radiation and tyrosine kinase inhibitors.
Topics: Anilides; Animals; Carcinoma, Neuroendocrine; Chemoradiotherapy; Female; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Proteins; Piperidines; Protein-Tyrosine Kinases; Pyridines; Quinazolines; Thyroid Neoplasms; Xenograft Model Antitumor Assays | 2020 |
Efficacy and Safety of Vandetanib in Progressive and Symptomatic Medullary Thyroid Cancer: Post Hoc Analysis From the ZETA Trial.
Topics: Adult; Carcinoma, Neuroendocrine; Disease Progression; Female; Humans; Male; Middle Aged; Piperidines; Quinazolines; Survival Analysis; Thyroid Neoplasms | 2020 |
Acute tubulointerstitial nephritis induced by the tyrosine kinase inhibitor vandetanib.
Topics: Aged; Humans; Male; Nephritis, Interstitial; Piperidines; Protein Kinase Inhibitors; Quinazolines; Thyroid Neoplasms | 2021 |
Vandetanib in a Child Affected by Neurofibromatosis Type 1 and Medullary Thyroid Carcinoma with Both
Topics: Adolescent; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Neuroendocrine; Germ-Line Mutation; Homozygote; Humans; Male; Neurofibromatosis 1; Neurofibromin 1; Piperidines; Proto-Oncogene Proteins c-ret; Quinazolines; Thyroid Neoplasms; Treatment Outcome | 2021 |
Real-World Efficacy and Safety of Cabozantinib and Vandetanib in Advanced Medullary Thyroid Cancer.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anilides; Antineoplastic Agents; Carcinoma, Neuroendocrine; Female; Germany; Humans; Male; Middle Aged; Piperidines; Progression-Free Survival; Protein Kinase Inhibitors; Pyridines; Quinazolines; Registries; Retrospective Studies; Thyroid Neoplasms; Time Factors; Young Adult | 2021 |
Vandetanib for the Management of Advanced Medullary Thyroid Cancer: A Real-World Multicenter Experience.
Topics: Carcinoma, Neuroendocrine; Disease-Free Survival; Female; Humans; Male; Middle Aged; Piperidines; Protein Kinase Inhibitors; Quinazolines; Republic of Korea; Retrospective Studies; Thyroid Neoplasms | 2020 |
Trends in the Diagnosis and Treatment of Patients with Medullary Thyroid Carcinoma in Korea.
Topics: Adolescent; Adult; Age Distribution; Aged; Aged, 80 and over; Carcinoma, Neuroendocrine; Child; Child, Preschool; Databases, Factual; Disease-Free Survival; Female; Forecasting; Humans; Infant; Infant, Newborn; Male; Middle Aged; National Health Programs; Piperidines; Quinazolines; Radiotherapy; Reoperation; Republic of Korea; Retrospective Studies; Sex Distribution; Thyroid Neoplasms; Thyroidectomy; Young Adult | 2020 |
Vandetanib versus Cabozantinib in Medullary Thyroid Carcinoma: A Focus on Anti-Angiogenic Effects in Zebrafish Model.
Topics: Angiogenesis Inhibitors; Anilides; Animals; Apoptosis; Carcinoma, Neuroendocrine; Cell Cycle; Cell Line, Tumor; Cell Survival; Disease Models, Animal; Embryo, Nonmammalian; Humans; Neovascularization, Pathologic; Neovascularization, Physiologic; Piperidines; Pyridines; Quinazolines; Thyroid Neoplasms; Zebrafish | 2021 |
HER inhibitor promotes BRAF/MEK inhibitor-induced redifferentiation in papillary thyroid cancer harboring BRAFV600E.
Topics: Benzimidazoles; Blotting, Western; Carcinoma, Papillary; Cell Cycle; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Humans; Imidazoles; Inhibitory Concentration 50; Lapatinib; MAP Kinase Kinase 1; Microscopy, Fluorescence; Mutation, Missense; Oximes; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Quinazolines; Receptor, ErbB-2; Reverse Transcriptase Polymerase Chain Reaction; Thyroid Neoplasms | 2017 |
Vandetanib and cabozantinib potentiate mitochondria-targeted agents to suppress medullary thyroid carcinoma cells.
Topics: Anilides; Animals; Carcinoma, Neuroendocrine; Cell Cycle; Cell Line, Tumor; Cell Survival; Disease Models, Animal; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Membrane Potential, Mitochondrial; Mice; Mitochondria; Mitochondrial Dynamics; Piperidines; Protein Kinase Inhibitors; Pyridines; Quinazolines; Thyroid Neoplasms; Xenograft Model Antitumor Assays | 2017 |
[Cabozantinib: Mechanism of action, efficacy and indications].
Topics: Anilides; Antineoplastic Agents; Bone Neoplasms; Carcinoma, Neuroendocrine; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Clinical Trials as Topic; Disease-Free Survival; Everolimus; Humans; Kidney Neoplasms; Lung Neoplasms; Male; Piperidines; Prostatic Neoplasms; Proto-Oncogene Proteins c-ret; Pyridines; Quinazolines; Receptor Protein-Tyrosine Kinases; Thyroid Neoplasms; Vascular Endothelial Growth Factor Receptor-2 | 2017 |
Outcomes of Children and Adolescents with Advanced Hereditary Medullary Thyroid Carcinoma Treated with Vandetanib.
Topics: Adolescent; Carcinoma, Medullary; Child; Disease Progression; Disease-Free Survival; Female; Germ-Line Mutation; Humans; Male; Multiple Endocrine Neoplasia Type 2a; Outcome Assessment, Health Care; Piperidines; Protein Kinase Inhibitors; Quinazolines; Thyroid Neoplasms | 2018 |
PI3K inhibitors IC87114 inhibits the migration and invasion of thyroid cancer cell in vitro and in vivo.
Topics: Adenine; Cell Line, Tumor; Cell Movement; Humans; Neoplasm Invasiveness; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Thyroid Neoplasms | 2018 |
Cabozantinib and Vandetanib in medullary thyroid carcinoma: mitochondrial function and its potential as a therapeutic target towards novel strategies to design anti-CSCs drugs.
Topics: Anilides; Humans; Mitochondria; Piperidines; Pyridines; Quinazolines; Thyroid Neoplasms | 2018 |
Pregnancy on vandetanib in metastatic medullary thyroid carcinoma associated with multiple endocrine neoplasia type 2B.
Topics: Adult; Carcinoma, Neuroendocrine; Female; Humans; Multiple Endocrine Neoplasia Type 2a; Mutation, Missense; Neoplasm Metastasis; Piperidines; Pregnancy; Quinazolines; Thyroid Neoplasms; Young Adult | 2018 |
Vandetanib has antineoplastic activity in anaplastic thyroid cancer, in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Cyclin D1; Dose-Response Relationship, Drug; ErbB Receptors; Gene Expression Regulation, Neoplastic; Humans; In Vitro Techniques; Mice; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Phosphorylation; Piperidines; Proto-Oncogene Proteins c-akt; Quinazolines; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Treatment Outcome; Xenograft Model Antitumor Assays | 2018 |
Mandibular metastasis as the first clinical indication of occult lung adenocarcinoma with multiple metastases: A case report.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged, 80 and over; Antineoplastic Agents; Biopsy; Bone Density Conservation Agents; Diagnosis, Differential; Diphosphonates; Female; Gefitinib; Humans; Imidazoles; Immunohistochemistry; Lung; Lung Neoplasms; Mandible; Mandibular Neoplasms; Neoplasm Grading; Neoplasm Staging; Quinazolines; Thyroid Neoplasms; Treatment Outcome; Zoledronic Acid | 2018 |
CRISPR/Cas9 Genome Editing of Epidermal Growth Factor Receptor Sufficiently Abolished Oncogenicity in Anaplastic Thyroid Cancer.
Topics: Afatinib; Antineoplastic Agents; Cell Cycle; Cell Death; Cell Line, Tumor; CRISPR-Cas Systems; ErbB Receptors; Gene Editing; Humans; Protein Kinase Inhibitors; Quinazolines; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms | 2018 |
Transcriptional targeting of oncogene addiction in medullary thyroid cancer.
Topics: Antineoplastic Agents; Bridged Bicyclo Compounds, Heterocyclic; Carcinoma, Neuroendocrine; Cell Line, Tumor; Cyclic N-Oxides; Cyclin-Dependent Kinases; Drug Resistance, Neoplasm; Drug Synergism; Enhancer Elements, Genetic; Gene Expression Regulation, Neoplastic; Humans; Indolizines; Introns; Molecular Targeted Therapy; Oncogene Addiction; Piperazines; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-ret; Pyridines; Pyridinium Compounds; Quinazolines; Thyroid Gland; Thyroid Neoplasms; Tissue Array Analysis; Transcription, Genetic | 2018 |
Appendix 2: Medullary Thyroid Cancer: eUpdate published online 19 February 2018 (http://www.esmo.org/Guidelines/Endocrine-and-Neuroendocrine-Cancers/Thyroid-cancer).
Topics: Administration, Oral; Carcinoma, Neuroendocrine; Clinical Trials, Phase III as Topic; Europe; Humans; Medical Oncology; Piperidines; Placebos; Practice Guidelines as Topic; Progression-Free Survival; Quinazolines; Randomized Controlled Trials as Topic; Societies, Medical; Thyroid Neoplasms | 2018 |
Vandetanib Tumor Shrinkage in Metastatic Medullary Thyroid Cancer Allowing Surgical Resection of the Primary Site: A Case Report.
Topics: Calcitonin; Carcinoembryonic Antigen; Carcinoma, Neuroendocrine; Child; Humans; Lung Neoplasms; Male; Piperidines; Quinazolines; Thyroid Neoplasms; Treatment Outcome; Tumor Burden | 2019 |
Primary Adrenal Insufficiency During Lenvatinib or Vandetanib and Improvement of Fatigue After Cortisone Acetate Therapy.
Topics: Addison Disease; Adult; Aged; Carcinoma, Neuroendocrine; Child; Cortisone; Dose-Response Relationship, Drug; Fatigue; Female; Follow-Up Studies; Humans; Male; Middle Aged; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Quinazolines; Quinolines; Thyroid Neoplasms; Treatment Outcome; Young Adult | 2019 |
Evodiamine Suppresses Survival, Proliferation, Migration and Epithelial-Mesenchymal Transition of Thyroid Carcinoma Cells.
Topics: Androstadienes; Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Drug Synergism; Epithelial-Mesenchymal Transition; Gene Expression Regulation, Neoplastic; Humans; Phosphorylation; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Quinazolines; Signal Transduction; Thyroid Neoplasms; Wortmannin | 2018 |
Rare complications of multikinase inhibitor treatment.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma; Carcinoma, Medullary; Female; Follow-Up Studies; Heart Failure; Humans; Intestinal Perforation; Kaplan-Meier Estimate; Male; Middle Aged; Oophoritis; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Quinazolines; Quinolines; Retrospective Studies; Risk Factors; Sorafenib; Thrombocytopenia; Thyroid Neoplasms; Time Factors; Young Adult | 2018 |
Tyrosine Kinase Inhibitor Use and Wound Healing in Tracheoesophageal Punctures.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Esophagus; Female; Humans; Laryngectomy; Male; Middle Aged; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Punctures; Quinazolines; Quinolines; Speech Disorders; Surgical Wound; Thyroid Neoplasms; Trachea; Wound Healing | 2019 |
Evodiamine in combination with histone deacetylase inhibitors has synergistic cytotoxicity in thyroid carcinoma cells.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma; Cell Line, Tumor; Drug Screening Assays, Antitumor; Drug Synergism; Histone Deacetylase Inhibitors; Humans; Quinazolines; Reactive Oxygen Species; Thyroid Neoplasms | 2019 |
A rare cutaneous phototoxic rash after vandetanib therapy in a patient with thyroid cancer: A case report.
Topics: Adult; Antineoplastic Agents; Dermatitis, Phototoxic; Drug-Related Side Effects and Adverse Reactions; Humans; Male; Piperidines; Quinazolines; Thyroid Neoplasms | 2019 |
Case records of the Massachusetts General Hospital. Case 5-2013. A 52-year-old woman with a mass in the thyroid.
Topics: Biopsy, Fine-Needle; Calcitonin; Carcinoma, Neuroendocrine; Diagnosis, Differential; Female; Humans; Lymph Nodes; Lymphatic Diseases; Middle Aged; Neck; Piperidines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Thyroid Gland; Thyroid Neoplasms; Thyroid Nodule; Thyrotropin; Tomography, X-Ray Computed; Ultrasonography | 2013 |
Toxic cardiomyopathy leading to fatal acute cardiac failure related to vandetanib: a case report with histopathological analysis.
Topics: Adult; Carcinoma, Neuroendocrine; Cardiomyopathies; Clinical Trials, Phase III as Topic; Fatal Outcome; Female; Heart Failure; Humans; Male; Piperidines; Protein Kinase Inhibitors; Quinazolines; Thyroid Neoplasms | 2013 |
Mitochondria-targeted nitroxide, Mito-CP, suppresses medullary thyroid carcinoma cell survival in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Carcinoma, Neuroendocrine; Cell Line, Tumor; Cell Survival; Cyclic N-Oxides; Drug Delivery Systems; Female; Humans; Mice; Mice, Nude; Mitochondria; Nitrogen Oxides; Organophosphorus Compounds; Piperidines; Proto-Oncogene Mas; Quinazolines; Thyroid Neoplasms; Xenograft Model Antitumor Assays | 2013 |
Thyroid cancer cell resistance to gefitinib depends on the constitutive oncogenic activation of the ERK pathway.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Genes, ras; Humans; MAP Kinase Signaling System; Mutation; Neoplasm Invasiveness; Phosphorylation; Proto-Oncogene Proteins B-raf; Quinazolines; Thyroid Neoplasms | 2013 |
Pretherapeutic drug evaluation by tumor xenografting in anaplastic thyroid cancer.
Topics: Animals; Apoptosis; Benzazepines; Cell Proliferation; Drug Evaluation, Preclinical; Humans; Male; Mice; Mice, Nude; Middle Aged; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Quinazolines; Random Allocation; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Treatment Outcome; Xenograft Model Antitumor Assays | 2013 |
Heparin-binding EGF-like growth factor enhances the activity of invasion and metastasis in thyroid cancer cells.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Neutralizing; Cell Line, Tumor; Cell Proliferation; Chemotaxis; Diphtheria Toxin; ErbB Receptors; Heparin-binding EGF-like Growth Factor; Humans; Intercellular Signaling Peptides and Proteins; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Quinazolines; Receptor, ErbB-4; RNA, Messenger; Thyroid Neoplasms; Tyrphostins | 2013 |
Reversal of Cushing's syndrome by vandetanib in medullary thyroid carcinoma.
Topics: Adrenocorticotropic Hormone; Calcitonin; Carcinoma, Neuroendocrine; Cushing Syndrome; Deamino Arginine Vasopressin; Humans; Lymphatic Metastasis; Male; Middle Aged; Paraneoplastic Syndromes; Piperidines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Thyroid Neoplasms | 2013 |
Tumour markers fluctuations in patients with medullary thyroid carcinoma receiving long-term RET inhibitor therapy: ordinary lapping or alarming waves foreshadowing disease progression?
Topics: Anilides; Biomarkers, Tumor; Calcitonin; Carcinoembryonic Antigen; Carcinoma, Neuroendocrine; Disease Progression; Humans; Piperidines; Proto-Oncogene Proteins c-ret; Pyridines; Quinazolines; Thyroid Neoplasms | 2013 |
Changes in signaling pathways induced by vandetanib in a human medullary thyroid carcinoma model, as analyzed by reverse phase protein array.
Topics: Adult; Animals; Carcinoma, Neuroendocrine; Cell Line, Tumor; Cell Proliferation; Humans; MAP Kinase Signaling System; Mice; Piperidines; Proto-Oncogene Mas; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Thyroid Neoplasms | 2014 |
Tyrosine kinase inhibitor treatments in patients with metastatic thyroid carcinomas: a retrospective study of the TUTHYREF network.
Topics: Adenocarcinoma; Adenocarcinoma, Follicular; Adenoma, Oxyphilic; Adult; Aged; Antineoplastic Agents; Bone Neoplasms; Carcinoma; Carcinoma, Neuroendocrine; Carcinoma, Papillary; Disease-Free Survival; Female; Humans; Indoles; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Piperidines; Pleural Neoplasms; Protein-Tyrosine Kinases; Pyrroles; Quinazolines; Retrospective Studies; Sorafenib; Sunitinib; Thyroid Cancer, Papillary; Thyroid Neoplasms; Treatment Outcome | 2014 |
Early development of a celiac trunk aneurysm during anti-vascular endothelial growth factor receptor therapy.
Topics: Aged; Aneurysm; Celiac Artery; Enzyme Inhibitors; Female; Humans; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Thyroid Neoplasms; Tomography, X-Ray Computed; Treatment Outcome; Tyrphostins; Withholding Treatment | 2014 |
Vandetanib successfully controls medullary thyroid cancer-related Cushing syndrome in an adolescent patient.
Topics: Adolescent; Adrenocorticotropic Hormone; Carcinoma, Neuroendocrine; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Cushing Syndrome; Humans; Male; Multiple Endocrine Neoplasia Type 2b; Neoplasms, Second Primary; Piperidines; Protein-Tyrosine Kinases; Quinazolines; Thyroid Neoplasms | 2014 |
Involvement of G-quadruplex structures in regulation of human RET gene expression by small molecules in human medullary thyroid carcinoma TT cells.
Topics: Apoptosis; Base Sequence; Carcinoma, Neuroendocrine; Cell Line; Cell Line, Tumor; G-Quadruplexes; Gene Expression Regulation, Neoplastic; Humans; Nucleotide Motifs; Promoter Regions, Genetic; Protein Binding; Proto-Oncogene Mas; Proto-Oncogene Proteins c-ret; Quinazolines; Thyroid Neoplasms; Transcriptional Activation | 2015 |
Vandetanib-associated alopecia areata in a patient with metastatic medullary thyroid cancer.
Topics: Adult; Alopecia Areata; Carcinoma, Neuroendocrine; Humans; Male; Piperidines; Quinazolines; Thyroid Neoplasms | 2015 |
Photo-induced erythema multiforme associated with vandetanib administration.
Topics: Aged; Biopsy, Needle; Carcinoma, Medullary; Erythema Multiforme; Follow-Up Studies; Humans; Immunohistochemistry; Male; Neoplasm Staging; Photosensitivity Disorders; Piperidines; Quinazolines; Risk Assessment; Thyroid Neoplasms; Thyroidectomy | 2014 |
Medullary thyroid cancer in the era of tyrosine kinase inhibitors: to treat or not to treat--and with which drug--those are the questions.
Topics: Anilides; Carcinoma, Neuroendocrine; DNA Mutational Analysis; Humans; Male; Middle Aged; Piperidines; Precision Medicine; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Quinazolines; Thyroid Neoplasms; Thyroidectomy | 2014 |
Vandetanib for the treatment of advanced medullary thyroid cancer outside a clinical trial: results from a French cohort.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Neuroendocrine; Child; Female; France; Humans; Male; Middle Aged; Piperidines; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Risk Factors; Thyroid Neoplasms; Time Factors; Treatment Outcome; Young Adult | 2015 |
Dual inhibition of HDAC and EGFR signaling with CUDC-101 induces potent suppression of tumor growth and metastasis in anaplastic thyroid cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma; Cell Cycle; Cell Line, Tumor; DNA, Neoplasm; Dose-Response Relationship, Drug; Gene Expression Regulation, Neoplastic; High-Throughput Screening Assays; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Mice; Molecular Targeted Therapy; Mutation; Neoplasm Proteins; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Small Molecule Libraries; Thyroid Neoplasms; Xenograft Model Antitumor Assays | 2015 |
Preclinical testing of selective Aurora kinase inhibitors on a medullary thyroid carcinoma-derived cell line.
Topics: Aurora Kinase A; Aurora Kinase B; Azepines; Carcinoma, Neuroendocrine; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; Humans; Organophosphates; Pyrimidines; Quinazolines; Thyroid Neoplasms | 2016 |
Rapid response of hypercortisolism to vandetanib treatment in a patient with advanced medullary thyroid cancer and ectopic Cushing syndrome.
Topics: Adult; Carcinoma, Neuroendocrine; Cushing Syndrome; Disease Progression; Female; Humans; Neoplasm Staging; Piperidines; Quinazolines; Thyroid Neoplasms; Treatment Outcome | 2015 |
Use of Vandetanib in Metastatic Medullary Carcinoma of Thyroid in a Pediatric Patient With Multiple Endocrine Neoplasia 2B.
Topics: Antineoplastic Agents; Carcinoma, Neuroendocrine; Child; Humans; Male; Multiple Endocrine Neoplasia Type 2a; Piperidines; Quinazolines; Thyroid Neoplasms | 2016 |
High Affinity Pharmacological Profiling of Dual Inhibitors Targeting RET and VEGFR2 in Inhibition of Kinase and Angiogeneis Events in Medullary Thyroid Carcinoma.
Topics: Angiogenesis Inhibitors; Anilides; Carcinoma, Neuroendocrine; Databases, Chemical; Drug Discovery; Humans; Imidazoles; Indoles; Molecular Docking Simulation; Molecular Structure; Niacinamide; Oligonucleotides; Piperidines; Protein Binding; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-ret; Pyrazoles; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sunitinib; Thyroid Neoplasms; Vascular Endothelial Growth Factor Receptor-2 | 2015 |
Prognostic Value of Serum Tumor Markers in Medullary Thyroid Cancer Patients Undergoing Vandetanib Treatment.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Calcitonin; Carcinoembryonic Antigen; Carcinoma, Neuroendocrine; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Piperidines; Prognosis; Protein-Tyrosine Kinases; Quinazolines; Thyroid Neoplasms | 2015 |
A Pyrazolo[3,4-d]pyrimidin-4-amine Derivative Containing an Isoxazole Moiety Is a Selective and Potent Inhibitor of RET Gatekeeper Mutants.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Survival; Drug Design; Drug Resistance, Neoplasm; Humans; Models, Molecular; Molecular Docking Simulation; Mutation; Phosphorylation; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-ret; Quinazolines; Structure-Activity Relationship; Substrate Specificity; Thyroid Neoplasms | 2016 |
Biometrical issues in the analysis of adverse events within the benefit assessment of drugs.
Topics: Adverse Drug Reaction Reporting Systems; Androstenes; Antineoplastic Agents; Clinical Trials as Topic; Drug Approval; Drug Industry; Drug-Related Side Effects and Adverse Reactions; Female; Follow-Up Studies; Germany; Humans; Male; Piperidines; Prostatic Neoplasms; Quinazolines; Survival Rate; Thyroid Neoplasms | 2016 |
Carfilzomib potentiates CUDC-101-induced apoptosis in anaplastic thyroid cancer.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p21; Drug Synergism; G2 Phase Cell Cycle Checkpoints; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Mutation; Oligopeptides; Poly(ADP-ribose) Polymerases; Quinazolines; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms | 2016 |
cabozantinib (COMETRIQ⁰). In medullary thyroid cancer: more harmful than beneficial, as is vandetanib.
Topics: Anilides; Antineoplastic Agents; Carcinoma, Neuroendocrine; Female; Humans; Male; Piperidines; Protein Kinase Inhibitors; Pyridines; Quality of Life; Quinazolines; Thyroid Neoplasms | 2016 |
MicroRNA-375/SEC23A as biomarkers of the in vitro efficacy of vandetanib.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Carcinoma, Neuroendocrine; Cell Line; Cell Line, Tumor; Cell Proliferation; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Male; MicroRNAs; Middle Aged; Piperidines; Quinazolines; RNA Interference; Thyroid Neoplasms; Vesicular Transport Proteins | 2016 |
Comprehensive Genomic Profiling of Clinically Advanced Medullary Thyroid Carcinoma.
Topics: Aged; Anilides; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Neuroendocrine; Cyclin D1; Cyclin-Dependent Kinase Inhibitor p16; Drug Resistance, Neoplasm; Everolimus; Female; Fibroblast Growth Factor 3; Fibroblast Growth Factors; Gene Amplification; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Male; Methionine; Middle Aged; Molecular Targeted Therapy; Mutation; Piperidines; Proto-Oncogene Proteins c-ret; Proto-Oncogene Proteins p21(ras); Pyridines; Quinazolines; Threonine; Thyroid Neoplasms | 2016 |
Prognostic markers and response to vandetanib therapy in sporadic medullary thyroid cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Medullary; Female; Humans; Male; Middle Aged; Mutation; Piperidines; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Mas; Proto-Oncogene Proteins c-ret; Quinazolines; Thyroid Neoplasms; Treatment Outcome | 2016 |
[Metastatic medullary thyroid carcinoma in a child with multiple endocrine neoplasia 2B. Efficiency of medium-term treatment with vandetanib without thyroid surgery].
Topics: Carcinoma, Neuroendocrine; Child; Female; Humans; Lung Neoplasms; Multiple Endocrine Neoplasia Type 2b; Piperidines; Protein Kinase Inhibitors; Quinazolines; Thyroid Neoplasms | 2016 |
Long-Term Control of Hypercortisolism by Vandetanib in a Case of Medullary Thyroid Carcinoma with a Somatic RET Mutation.
Topics: Calcitonin; Carcinoma, Neuroendocrine; Cushing Syndrome; Cytoreduction Surgical Procedures; Humans; Hydrocortisone; Male; Middle Aged; Neck Dissection; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-ret; Quinazolines; Thyroid Neoplasms; Thyroidectomy | 2017 |
Proteomics study of medullary thyroid carcinomas expressing RET germ-line mutations: identification of new signaling elements.
Topics: Animals; Antineoplastic Agents; Carcinoma, Medullary; Epidermal Growth Factor; ErbB Receptors; Female; Gefitinib; Germ-Line Mutation; Humans; Mice; Mice, Nude; Multiple Endocrine Neoplasia Type 2a; Multiple Endocrine Neoplasia Type 2b; Oncogene Proteins; Phosphorylation; Proteomics; Proto-Oncogene Proteins c-ret; Quinazolines; Signal Transduction; Thyroid Neoplasms; Tyrosine | 2009 |
A case report of thyroid cancer showing a remarkable effect of gefitinib.
Topics: Antineoplastic Agents; Brain Neoplasms; Carcinoma, Papillary; Female; Gefitinib; Head and Neck Neoplasms; Humans; Incidental Findings; Lung Neoplasms; Lymph Nodes; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Multiple Primary; Quinazolines; Thyroid Neoplasms; Tomography, X-Ray Computed; Treatment Outcome; Ultrasonography | 2009 |
Oncocytic, focally anaplastic, thyroid cancer responding to erlotinib.
Topics: Aged; Carcinoma; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Point Mutation; Protein Kinase Inhibitors; Quinazolines; Thyroid Neoplasms; Tomography, X-Ray Computed | 2009 |
Inhibition of Src with AZD0530 reveals the Src-Focal Adhesion kinase complex as a novel therapeutic target in papillary and anaplastic thyroid cancer.
Topics: Antineoplastic Agents; Benzodioxoles; Carcinoma; Carcinoma, Papillary; Cell Culture Techniques; Cell Proliferation; Drug Delivery Systems; Drug Evaluation, Preclinical; Enzyme Activation; Focal Adhesion Protein-Tyrosine Kinases; Humans; Phosphorylation; Protein Binding; Protein Kinase Inhibitors; Proto-Oncogene Proteins pp60(c-src); Quinazolines; Thyroid Neoplasms; Tumor Cells, Cultured | 2009 |
The Ca2+-calmodulin-dependent kinase II is activated in papillary thyroid carcinoma (PTC) and mediates cell proliferation stimulated by RET/PTC.
Topics: Amino Acid Sequence; Animals; Calcium Signaling; Calcium-Calmodulin-Dependent Protein Kinase Type 2; Calmodulin; Carcinoma, Papillary; Cell Division; Enzyme Activation; Estrenes; Extracellular Signal-Regulated MAP Kinases; Humans; MAP Kinase Signaling System; Molecular Sequence Data; Mutation; Neoplasm Proteins; Oncogene Protein p21(ras); Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-ret; Pyrrolidinones; Quinazolines; Rats; Thyroid Neoplasms; Type C Phospholipases | 2010 |
Erlotinib enhances the proapoptotic activity of cytotoxic agents and synergizes with paclitaxel in poorly-differentiated thyroid carcinoma cells.
Topics: Adenocarcinoma, Follicular; Antineoplastic Agents; Apoptosis; Blotting, Western; Cell Differentiation; Cell Proliferation; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Humans; Paclitaxel; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Thyroid Neoplasms; Tumor Cells, Cultured | 2010 |
Anti-proliferative effects of evodiamine on human thyroid cancer cell line ARO.
Topics: Apoptosis; Blotting, Western; Caspases; Cell Cycle; Cell Cycle Proteins; Cell Division; Cell Line, Tumor; Cell Proliferation; DNA Fragmentation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Evodia; G2 Phase; Humans; In Situ Nick-End Labeling; Indole Alkaloids; Plant Extracts; Poly(ADP-ribose) Polymerases; Quinazolines; Thyroid Neoplasms; Time Factors | 2010 |
The tyrosine kinase inhibitor ZD6474 blocks proliferation of RET mutant medullary thyroid carcinoma cells.
Topics: Carcinoma, Medullary; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Humans; Mutation; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-ret; Quinazolines; Signal Transduction; Thyroid Neoplasms; Transforming Growth Factor alpha; Vascular Endothelial Growth Factor Receptor-2 | 2011 |
AZD1152 negatively affects the growth of anaplastic thyroid carcinoma cells and enhances the effects of oncolytic virus dl922-947.
Topics: Animals; Antineoplastic Agents; Cell Death; Cell Proliferation; Combined Modality Therapy; Drug Synergism; Female; Humans; Mice; Mice, Nude; Oncolytic Virotherapy; Oncolytic Viruses; Organophosphates; Protein Kinase Inhibitors; Quinazolines; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Tumor Cells, Cultured; Up-Regulation; Xenograft Model Antitumor Assays | 2011 |
Targeted therapy of VEGFR2 and EGFR significantly inhibits growth of anaplastic thyroid cancer in an orthotopic murine model.
Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Epidermal Growth Factor; ErbB Receptors; Humans; Immunoblotting; In Situ Nick-End Labeling; Magnetic Resonance Imaging; Male; Mice; Mice, Nude; Neovascularization, Pathologic; Phosphorylation; Piperidines; Platelet Endothelial Cell Adhesion Molecule-1; Quinazolines; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Tumor Burden; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays | 2011 |
Metabolic imaging allows early prediction of response to vandetanib.
Topics: Aged; Animals; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cyclins; Dihydroxyphenylalanine; Down-Regulation; Female; Fluorodeoxyglucose F18; G1 Phase; Glucose; Humans; Male; Mice; Mice, SCID; Microarray Analysis; Piperidines; Positron-Emission Tomography; Proto-Oncogene Proteins c-ret; Quality Control; Quinazolines; Radiopharmaceuticals; Resting Phase, Cell Cycle; RNA, Neoplasm; Signal Transduction; Thymidine; Thyroid Neoplasms; Tomography, Emission-Computed | 2011 |
Good clinical response to erlotinib in a patient with anaplastic thyroid carcinoma harboring an epidermal growth factor somatic mutation, L858R, in exon 21.
Topics: Adenocarcinoma, Papillary; Aged; Antineoplastic Agents; Carcinoma, Signet Ring Cell; DNA Mutational Analysis; Epidermal Growth Factor; Erlotinib Hydrochloride; Exons; Female; Humans; Immunohistochemistry; Mutation; Polymerase Chain Reaction; Quinazolines; Thyroid Neoplasms | 2011 |
[New therapeutic options for advanced thyroid cancer].
Topics: Antineoplastic Agents; Benzenesulfonates; Humans; Indoles; Niacinamide; Phenylurea Compounds; Piperidines; Pyridines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Thyroid Neoplasms | 2011 |
Updates in the management of medullary thyroid cancer.
Topics: Carcinoma, Neuroendocrine; Contraindications; Humans; Multiple Endocrine Neoplasia; Mutation; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-ret; Quinazolines; Research; Syndrome; Thyroid Neoplasms | 2011 |
Tumor-to-tumor metastasis: lung adenocarcinoma metastasizing to a follicular variant of papillary thyroid carcinoma.
Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoma; Carcinoma, Papillary; Combined Modality Therapy; DNA Mutational Analysis; DNA, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Mutation; Quinazolines; Thyroid Cancer, Papillary; Thyroid Neoplasms; Treatment Outcome | 2011 |
Vandetanib: first global approval.
Topics: Animals; Antineoplastic Agents; Carcinoma, Neuroendocrine; Drug Approval; Drug Design; Humans; Neoplasm Metastasis; Piperidines; Quinazolines; Thyroid Neoplasms; Vascular Endothelial Growth Factor Receptor-2 | 2011 |
A case of colorectal cancer with double-activating epidermal growth factor receptor mutations.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Female; Fluorouracil; Humans; Immunohistochemistry; Leucovorin; Lung Neoplasms; Mutation; Neoplasms, Second Primary; Organoplatinum Compounds; Quinazolines; Thyroid Neoplasms; Transcriptional Activation; Treatment Failure; Treatment Outcome | 2011 |
Progress in molecular targeted therapy for thyroid cancer: vandetanib in medullary thyroid cancer.
Topics: Carcinoma, Neuroendocrine; Female; Humans; Male; Piperidines; Quinazolines; Thyroid Neoplasms | 2012 |
Pharmacotherapy: vandetanib-a new therapeutic option in advanced medullary thyroid cancer.
Topics: Female; Humans; Male; Piperidines; Quinazolines; Thyroid Neoplasms | 2011 |
Completing the Arc: targeted inhibition of RET in medullary thyroid cancer.
Topics: Carcinoma, Neuroendocrine; Female; Humans; Male; Piperidines; Quinazolines; Thyroid Neoplasms | 2012 |
Unusual adverse event with vandetanib in metastatic medullary thyroid cancer.
Topics: Carcinoma, Neuroendocrine; Humans; Male; Middle Aged; Neoplasm Metastasis; Piperidines; Quinazolines; Thyroid Neoplasms | 2012 |
Treatment of metastatic medullary thyroid cancer with vandetanib: need to stratify patients on basis of calcitonin doubling time.
Topics: Female; Humans; Male; Piperidines; Quinazolines; Thyroid Neoplasms | 2012 |
Unusual short-term complete response to two regimens of cytotoxic chemotherapy in a patient with poorly differentiated thyroid carcinoma.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Cisplatin; Combined Modality Therapy; Doxorubicin; Fatal Outcome; Female; Fluorodeoxyglucose F18; Humans; Indoles; Iodine Radioisotopes; Lung Neoplasms; Middle Aged; Niacinamide; Paclitaxel; Phenylurea Compounds; Piperidines; Pyridines; Pyrroles; Quinazolines; Radiopharmaceuticals; Sorafenib; Sunitinib; Thyroid Neoplasms; Thyroidectomy; Tomography, X-Ray Computed | 2012 |
Treating advanced radioresistant differentiated thyroid cancer.
Topics: Adenocarcinoma, Follicular; Antineoplastic Agents; Carcinoma; Carcinoma, Papillary; Female; Humans; Male; Piperidines; Quinazolines; Thyroid Cancer, Papillary; Thyroid Neoplasms | 2012 |
First do no harm: counting the cost of chasing drug efficacy.
Topics: Adenocarcinoma, Follicular; Antineoplastic Agents; Carcinoma; Carcinoma, Papillary; Female; Humans; Male; Piperidines; Quinazolines; Thyroid Cancer, Papillary; Thyroid Neoplasms | 2012 |
The safety risks of innovation: the FDA's Expedited Drug Development Pathway.
Topics: Anticoagulants; Antineoplastic Agents; Benzimidazoles; beta-Alanine; Carcinoma, Neuroendocrine; Clinical Trials as Topic; Dabigatran; Drug Approval; Efficiency, Organizational; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Patient Safety; Piperidines; Propylene Glycols; Quinazolines; Risk; Sphingosine; Stroke; Thyroid Neoplasms; Time Factors; United States; United States Food and Drug Administration | 2012 |
Vandetanib: too dangerous in medullary thyroid cancer.
Topics: Antineoplastic Agents; Carcinoma, Neuroendocrine; Evidence-Based Medicine; Humans; Patient Safety; Piperidines; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Thyroid Neoplasms; Treatment Outcome | 2012 |
ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases.
Topics: 3T3 Cells; Animals; Carcinoma, Papillary; Cell Transformation, Neoplastic; Drosophila Proteins; Enzyme Inhibitors; Mice; Mice, Inbred BALB C; Mice, Nude; Phosphorylation; Piperidines; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-ret; Quinazolines; Receptor Protein-Tyrosine Kinases; Signal Transduction; Thyroid Neoplasms; Vascular Endothelial Growth Factor Receptor-2 | 2002 |
Regulation of p27Kip1 protein levels contributes to mitogenic effects of the RET/PTC kinase in thyroid carcinoma cells.
Topics: Cell Cycle Proteins; Cell Line, Tumor; Cyclin D; Cyclin E; Cyclin-Dependent Kinase Inhibitor p27; Cyclins; Cysteine Endopeptidases; Enzyme Inhibitors; Gene Rearrangement; Humans; MAP Kinase Signaling System; Multienzyme Complexes; Oncogene Proteins, Fusion; Piperidines; Proteasome Endopeptidase Complex; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-ret; Pyrazoles; Pyrimidines; Quinazolines; Receptor Protein-Tyrosine Kinases; Thyroid Neoplasms; Tumor Suppressor Proteins; Up-Regulation | 2004 |
Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitors.
Topics: Carcinoma, Medullary; Catalytic Domain; Cell Line; Drug Resistance; Enzyme Inhibitors; Mitogens; Piperidines; Point Mutation; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-ret; Pyrazoles; Pyrimidines; Quinazolines; Receptor Protein-Tyrosine Kinases; Signal Transduction; Thyroid Neoplasms; Valine | 2004 |
Epidermal growth factor receptor (EGFR) is overexpressed in anaplastic thyroid cancer, and the EGFR inhibitor gefitinib inhibits the growth of anaplastic thyroid cancer.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma; Carcinoma, Papillary; Cell Proliferation; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Humans; Mice; Mice, Nude; Paclitaxel; Phosphorylation; Quinazolines; Thyroid Neoplasms; Transforming Growth Factor alpha; Tumor Cells, Cultured | 2004 |
Identification of RET kinase inhibitors as potential new treatment for sporadic and inherited thyroid cancer.
Topics: Carcinoma, Medullary; Carcinoma, Papillary; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Male; Mutation; Piperidines; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-ret; Quinazolines; Receptor Protein-Tyrosine Kinases; Sensitivity and Specificity; Thyroid Neoplasms; Treatment Outcome | 2004 |
Efficacy of epidermal growth factor receptor-targeted molecular therapy in anaplastic thyroid cancer cell lines.
Topics: Animals; Carcinoma; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Female; Gefitinib; Humans; Mice; Mice, Inbred BALB C; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Neoplasm Transplantation; Phosphorylation; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Quinazolines; Thyroid Neoplasms; Transplantation, Heterologous | 2005 |
ZD6474 suppresses oncogenic RET isoforms in a Drosophila model for type 2 multiple endocrine neoplasia syndromes and papillary thyroid carcinoma.
Topics: Animals; Carcinoma, Papillary; Disease Models, Animal; Drosophila; Drosophila Proteins; ErbB Receptors; Eye Abnormalities; Multiple Endocrine Neoplasia Type 2a; Multiple Endocrine Neoplasia Type 2b; Piperidines; Protein Isoforms; Proto-Oncogene Proteins c-ret; Quinazolines; raf Kinases; ras Proteins; Receptor Protein-Tyrosine Kinases; Thyroid Neoplasms | 2005 |
Additive antitumor effects of gefitinib and imatinib on anaplastic thyroid cancer cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzamides; Cell Line, Tumor; DNA Primers; Drug Synergism; Female; Gefitinib; Humans; Imatinib Mesylate; Mice; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; Thyroid Neoplasms | 2006 |
A rapid method for the purification of wild-type and V804M mutant ret catalytic domain: A tool to study thyroid cancer.
Topics: Amino Acid Substitution; Animals; Cell Line; Drug Resistance, Neoplasm; Enzyme Inhibitors; Humans; Piperidines; Point Mutation; Protein Structure, Tertiary; Proto-Oncogene Proteins c-ret; Pyrazoles; Pyrimidines; Quinazolines; Recombinant Proteins; Spodoptera; Thyroid Neoplasms | 2006 |
Targeting the EGF/VEGF-R system by tyrosine-kinase inhibitors--a novel antiproliferative/antiangiogenic strategy in thyroid cancer.
Topics: Carcinoma; Cell Culture Techniques; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Gefitinib; Humans; Piperidines; Protein Kinase Inhibitors; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Thyroid Neoplasms; Vascular Endothelial Growth Factor A | 2006 |
Differentiated thyroid cancer cell invasion is regulated through epidermal growth factor receptor-dependent activation of matrix metalloproteinase (MMP)-2/gelatinase A.
Topics: Adenocarcinoma, Follicular; Aprotinin; Blotting, Western; Carcinoma, Papillary; Cell Differentiation; Dipeptides; Enzyme Activation; Enzyme Inhibitors; Epidermal Growth Factor; ErbB Receptors; Flow Cytometry; Humans; Matrix Metalloproteinase 2; Matrix Metalloproteinase Inhibitors; Neoplasm Invasiveness; Protease Inhibitors; Protein Tyrosine Phosphatase, Non-Receptor Type 1; Protein Tyrosine Phosphatases; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; Serine Proteinase Inhibitors; Tetracyclines; Thyroid Neoplasms; Tumor Cells, Cultured; Tyrphostins | 2006 |
A transplantable human medullary thyroid carcinoma as a model for RET tyrosine kinase-driven tumorigenesis.
Topics: Aged; Animals; Calcitonin; Carcinoma, Medullary; Cell Line, Tumor; Cell Transformation, Neoplastic; Chromogranin A; Disease Models, Animal; ErbB Receptors; Humans; Karyotyping; Male; Mice; Mice, Nude; Mutation; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Mas; Proto-Oncogene Proteins c-ret; Quinazolines; Thyroid Neoplasms; Vascular Endothelial Growth Factor Receptor-1; Xenograft Model Antitumor Assays | 2007 |
The tyrosine kinase inhibitor, AZD2171, inhibits vascular endothelial growth factor receptor signaling and growth of anaplastic thyroid cancer in an orthotopic nude mouse model.
Topics: Animals; Apoptosis; Carcinoma; Cell Proliferation; Cells, Cultured; Endothelium, Vascular; Humans; Male; Mice; Mice, Nude; Quinazolines; Survival Rate; Thyroid Neoplasms; Umbilical Veins; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays | 2007 |
Gefitinib inhibition of drug resistance to doxorubicin by inactivating ABCG2 in thyroid cancer cell lines.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biomarkers, Tumor; Blotting, Western; Carcinoma; Cell Line, Tumor; Cell Proliferation; Culture Media; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; ErbB Receptors; Flow Cytometry; Fluorescent Antibody Technique; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; In Situ Nick-End Labeling; Neoplasm Proteins; Quinazolines; RNA, Neoplasm; Thyroid Neoplasms | 2007 |
Gefitinib (Iressa) potentiates the effect of ionizing radiation in thyroid cancer cell lines.
Topics: Adenocarcinoma, Follicular; Antineoplastic Agents; Carcinoma; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Down-Regulation; Drug Synergism; ErbB Receptors; Gefitinib; Humans; Phosphorylation; Quinazolines; Thyroid Neoplasms | 2008 |
Epidermal growth factor receptor signaling activates met in human anaplastic thyroid carcinoma cells.
Topics: Antineoplastic Agents; Butadienes; Carcinoma; Enzyme Inhibitors; ErbB Receptors; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; MAP Kinase Kinase Kinase 1; MAP Kinase Signaling System; Mitogen-Activated Protein Kinases; Nitriles; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins c-met; Quinazolines; RNA, Messenger; Suramin; Thyroid Neoplasms; Transforming Growth Factor alpha; Tumor Cells, Cultured; Tyrphostins | 2000 |